Kyle Mikson (Canaccord) asked about the near- and long-term ASP and volume impact of the UnitedHealth and ACS wins, and views on the late-August USPSTF meeting.
AmirAli Talasaz said ~70 million lives (~60% of the market) are now covered and the UHG win could be a volume tailwind, letting Guardant build the under-65 commercial base, but ASP upside will take time and patience as they work through payer conversations and collection history; the USPSTF outlook is unchanged with the August meeting expected to proceed.
Subbu Nambi (Guggenheim) asked about the puts and takes on the raised ~50% oncology volume guide, the tough Q3 Guardant360 comp, and how the UnitedHealth coverage came about.
Helmy Eltoukhy pointed to broad-based strength (Guardant360 >30%, Tissue higher, Reveal >100%) giving confidence in the 50% full-year volume mark despite tough comps; AmirAli said the United decision was unexpected and sooner than anticipated, built on a multi-year relationship, but they expect no other major payer wins near-term.
Puneet Souda (Leerink) asked where Guardant360 sits on its S-curve of growth and what is driving Shield upside.
Helmy said the genome-wide-methylation-integrated test is only 'scratching the surface,' with a big future multiplier from testing patients at every progression; AmirAli attributed Shield's strong 22,000-test sequential step-up to Quest co-promotion, DTC, and field-force additions with nonlinear productivity gains, while guiding conservatively for H2 (~12,000 sequential adds at the midpoint).
Mark Massaro (BTIG) asked how Guardant will negotiate pricing with UnitedHealth given the $1,495 ADLT rate reference and whether ACS/NCCN de-risk USPSTF.
AmirAli said they just received coverage and will work through the typical process where Medicare pricing is the centerpiece and pricing is transparent; the United decision ahead of USPSTF is drawing payer attention, but no additional wins are baked into guidance for the rest of the year.
Dan Brennan (TD Cowen) asked about the realized-price assumptions from the Guardant360 ADLT process and the drop-through/reinvestment of any revenue upside.
Michael Bell said the ADLT process targets a price of $8,455 (up from $5,000 Medicare), an immediate Medicare increase that takes 12-24 months to flow to MA and commercial; incremental gross profit would be split between dropping to the bottom line (potentially accelerating the Q4 2027 breakeven) and reinvesting in innovation and oncology commercial operations.
Daniel Markowitz (Evercore) asked about progress toward the 2028 Investor Day targets and whether the ADLT list price implies a Guardant360 ASP nearer $5,000.
Bell said the 2028 revenue target was raised to $2.2 billion (implying >30% three-year growth) and current 36%-38% guidance keeps them tracking well, though they are not changing the target now; a long-term Guardant360 ASP around $5,000 (roughly 60% of the Medicare rate) is achievable over 12-24 months.
Casey Woodring (JPMorgan) asked how therapy-monitoring volumes are tracking within Reveal's >100% growth and whether the G360 FDA approval is moving volumes.
Helmy called therapy monitoring an underappreciated, multi-million-test opportunity across ~1 million late-stage patients that could rival MRD, with strong uptake from existing Guardant360 ordering physicians; the FDA approval came late in the quarter under a phased launch, so it is having a positive but not yet full impact pending ADLT.
Kallum Titchmarsh (Morgan Stanley) asked for more color on Reveal Ultra's indication roadmap/commercial strategy and Shield multi-cancer opt-in rates.
Helmy kept specifics close but said development has gone very well, routinely hitting limits of detection well below one part per million, and that they will be thoughtful about indications, portfolio connectivity, and reimbursement timelines; AmirAli said Shield multi-cancer data collection is going very well with the majority of ordering physicians opting in to MCD reports.
Brad Bowers (Mizuho) asked about the profitability inflection given the lower-COGS Shield workflow and pending ADLT pricing.
Bell framed profitability alongside free-cash-flow burn, reaffirming end-2027 company breakeven; the ex-screening business is already adjusted EBITDA positive, screening burn should start ramping down in 2027 (breakeven in 2028), and a Guardant360 ADLT uplift could pull profitability forward.
Catherine Schulte (Baird) asked about timing of MolDX decisions on Reveal indications and the development behind the lower-COGS methylation-only Shield workflow.
Helmy said IO and breast are closest to the finish line, with hope for one or both by year-end and progress on chemo; AmirAli said the improved Shield workflow focuses on methylation-only content already in Shield V1, and algorithm updates plus multimodal Shield are generating an exciting performance-improvement pipeline.